From $50, to $750: Price of brain tumor, lymphoma medication has jumped 1,400 percent | FOX6Now.com

MIAMI, Florida — A drug maker is being accused of price gouging.

NextSource Biotechnology is under fire after the Wall Street Journal revealed the price of its 40-year-old cancer drug Lomustine has jumped 1,400 percent since 2013.

Lomustine treats brain tumors and Hodgkin’s Lymphoma. It’s the only drug of its kind on the market — with no generic alternative — letting the drug supplier raise costs for patients unchecked by market competition.

The drug used to cost about $50 per capsule for the highest dose. Now, the same treatment costs more than $750 — and the costs can quickly add up. Dosage is based on weight, and some patients need more than one capsule, making the drug’s price point completely out of reach.

Read complete article here:

From $50, to $750: Price of brain tumor, lymphoma medication has jumped 1,400 percent | FOX6Now.com.

Post a Comment

WP-SpamFree by Pole Position Marketing